Stockreport

TD Cowen Reiterates Buy Rating on ABCL After AbCellera Biologics Dosed First Participants of ABCL575 [Yahoo! Finance]

AbCellera Biologics Inc. - Common Shares  (ABCL) 
PDF Funds . On September 11, TD Cowen reiterated its Buy rating on AbCellera Biologics Inc. (NASDAQ:ABCL), without giving a price target. TD Cowen analyst Brendan Smith se [Read more]